M Lab Podcasts from MilliporeSigma and GEN

Digital Tools Push Single-Use Technology Challenges to the Side

In a previouspodcast [https://www.genengnews.com/resources/podcasts/gencast/virtual-collaborations-push-pharma-forward-during-pandemic/], we heard about the power of virtual collaborations during a pharmaceutical company’s push to meet their manufacturing goals during a global pandemic with much of the world on hold or scrambling to find solutions to fit their needs. Unfortunately, the coronavirus pandemic still rages on, yet the team at the M Lab™ [https://s.w.org/images/core/emoji/13.1.0/72x72/2122.png] Collaboration Centers from MilliporeSigma remains undaunted and ready to assist biomanufacturing scientists with their most challenging projects. In thisGENcast, we will hear how Pfizer was evaluating single-use technologies for some of their capital projects and how the team at the M Lab Collaboration Center was able to help them navigate challenges using remote demos and digital tools. While single-use technologies for biomanufacturing has tremendous benefits, there are always questions about how many of the parameters work, as well as customer concerns on scalability. Our podcast panelists will address how digital tools brought these companies together to tackle these critical single-use questions despite their physical distance. Panelists: [https://www.genengnews.com/wp-content/uploads/2020/09/kenny-150x150-1.jpg] Kenny Miller Sales Development Specialist Single-Use Technologies MilliporeSigma [https://www.genengnews.com/wp-content/uploads/2020/09/amy-150x150-1.jpg] Amy Newell MAP Customer Project Manager Pfizer The post Digital Tools Push Single-Use Technology Challenges to the Side [https://www.genengnews.com/resources/podcasts/gencast/digital-tools-push-single-use-technology-challenges-to-the-side-millipore/] appeared first on GEN - Genetic Engineering and Biotechnology News [https://www.genengnews.com].

Virtual Collaborations Push Pharma Forward During Pandemic

With regions of the world cycling through societal re-openings and shutdowns due to the ongoing coronavirus pandemic, pharma and life science companies are tasked with trying to find creative solutions that help keep production lines moving, as well as drive innovation forward. For instance, pharmaceutical manufacturers still need to meet critical project timelines so that patients receive the therapies they require. As such, many companies require varying levels of technical support to accomplish their goals—a scenario made much more difficult due to travel and in-person meeting restrictions. Thankfully, the resilient team at the M Lab™ [https://s.w.org/images/core/emoji/13.1.0/72x72/2122.png] Collaboration Centers from MilliporeSigma were able to work out virtual solutions to support their partner Vuab Pharma reach their manufacturing goals. Take a listen to this latest GENcast and see how the virtual world stepped up to help the pharma space. View Transcript of This Podcast [https://www.genengnews.com/wp-content/uploads/2020/08/GENCast-Vuab-Pharma-Transcript-MilliporeSigma.pdf]Panelists: [https://www.genengnews.com/wp-content/uploads/2020/08/paulk-150x150.jpg]Paul Kaschutnig, PhD Process Development Consultant MilliporeSigma [https://www.genengnews.com/wp-content/uploads/2020/08/marine-150x150.jpg]Marine Maszelin EMEA Senior Process Development Scientist MilliporeSigma [https://www.genengnews.com/wp-content/uploads/2020/08/ondrej-150x150.jpg]Ondřej Žítek Head of R&D Centre Vuab Pharma The post Virtual Collaborations Push Pharma Forward During Pandemic [https://www.genengnews.com/resources/podcasts/gencast/virtual-collaborations-push-pharma-forward-during-pandemic-millipore/] appeared first on GEN - Genetic Engineering and Biotechnology News [https://www.genengnews.com].

Trends in Bioprocess 4.0 and their Impact on Biomanufacturing

The biomanufacturing industry is currently undergoing a revolution in how it produces biopharmaceutical products. The driving force behind this paradigm shift is known as Bioprocess 4.0 or Industry 4.0. The approach focuses on how to apply data, predictive modeling, analytics, machine learning, artificial intelligence, automation, and technology for the digital transformation of biologics manufacturing. It’s all about using data from raw materials and bioproduction operations to optimize the process. The overall goals are to improve efficiency, lower costs, and help customers get their products to market faster. In this GEN podcast, we’ll hear from experts at MilliporeSigma on how the company is applying the principles of Bioprocess 4.0 to its own biomanufacturing strategy and operations. View Transcript of This Podcast [https://www.genengnews.com/wp-content/uploads/2020/05/GEBN-GENCast-Biopharma-4.0-Sterling-05-2020.pdf] Panelists: [https://www.genengnews.com/wp-content/uploads/2020/05/Jim-Neville-150x150.jpg] Jim Neville Director of Technology Management – Americas MilliporeSigma [https://www.genengnews.com/wp-content/uploads/2020/05/John-Cyganowski-150x150.jpg]John Cyganowski Director of Manufacturing Sciences & Technologies – Americas MilliporeSigma The post Trends in Bioprocess 4.0 and their Impact on Biomanufacturing [https://www.genengnews.com/resources/podcasts/gencast/trends-in-bioprocess-4-0-and-their-impact-on-biomanufacturing-millipore/] appeared first on GEN - Genetic Engineering and Biotechnology News [https://www.genengnews.com].